Sobi buys rare-disease drug emapalumab, zooms in on hematology and immunology

Rare diseases specialist Swedish Orphan Biovitrum (Sobi) has agreed to buy the drug emapalumab and is reorganizing to increase focus on late-stage development in hematology and immunology.